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Abstract
Background and Objective Sleep disturbances related to
reflux symptoms have a significant impact on the daily
lives of affected individuals. These analyses identified
clinical factors related to resolution of reflux-related sleep
disturbance in subjects treated with esomeprazole 20 mg
for 14 days.
Methods Data from the first 14 days of 2 similar ran-
domized, double-blind studies were pooled for subjects
experiencing frequent heartburn and related sleep distur-
bances receiving esomeprazole 20 mg (n = 357) or pla-
cebo (n = 346). A stepwise logistic regression analysis
was performed with pooled and individual study data to
evaluate relationships between clinical factors [treatment
(esomeprazole vs. placebo), run-in sleep disturbance fre-
quency, occurrence (yes/no) of 24-h, daytime, and night-
time heartburn (yes: C1 episode in 14-day treatment
period)] and complete sleep disturbance resolution (no
disturbances for 7 consecutive days).
Results Absence of daytime (p = 0.0018) or nighttime
(p\ 0.0001) heartburn during treatment was a significant
predictor of complete sleep disturbance resolution at
14 days for the total population, while higher run-in sleep
disturbance frequency (p\ 0.0001) was associated with a
lower likelihood of resolution. Esomeprazole treatment
was an independent significant predictor of improvement
across all endpoints (p\ 0.0001). A significant treatment
by run-in sleep disturbance interaction was observed for
complete resolution (p = 0.0231), indicating greater ther-
apeutic benefit with esomeprazole in subgroups with higher
run-in symptom frequency.
Conclusions Lower run-in sleep disturbance frequency,
no occurrence of daytime or nighttime heartburn during
therapy, and esomeprazole treatment predicted complete
reflux-related sleep disturbance resolution. The magnitude
of therapeutic benefit for esomeprazole 20 mg over pla-
cebo increased with increasing baseline sleep disturbance.
Key Points
Lower frequency of sleep disturbances during the
run-in period and absence of daytime and nighttime
reflux symptoms during treatment were associated
with a greater likelihood of resolution of reflux-
related sleep disturbances in the total population.
Treatment with esomeprazole 20 mg was a
significant predictor of sleep disturbance resolution
compared with placebo.
The therapeutic benefit of esomeprazole 20 mg over
placebo progressively increased as the frequency of
run-in sleep disturbances increased.
1 Introduction
Nighttime heartburn can have a significant impact on
individuals experiencing reflux symptoms. The impact of
nighttime heartburn is highlighted by the fact that
approximately 50–75 % of individuals with heartburn
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experience nocturnal reflux episodes that can cause awak-
ening [1, 2]. In fact, sleep disturbance is particularly
common among individuals with frequent heartburn [1–6].
Those who experience nocturnal symptoms are more likely
to have sleep disruptions, and the associated adverse con-
sequences, than those who experience only daytime
symptoms [7, 8]. Sleep disturbances associated with reflux
symptoms can lead to daytime fatigue, as well as signifi-
cant impairments in the performance of daily life activities,
work productivity, mood, and overall health-related quality
of life of the patients [1, 2, 5, 6, 9]. Emerging evidence
from clinical and non-clinical studies supports a relation-
ship among sleep, immune function, and inflammation
[10]. Sleep is believed to have a protective role, and con-
versely, decreased or dysfunctional/fragmented sleep is
associated with increased levels of pro-inflammatory
cytokines and greater susceptibility to infection [11]. Given
the importance of sleep disturbance in individuals with
nighttime heartburn, it is important to understand clinical
factors that are predictive of resolution/relief of sleep
disturbances.
Esomeprazole is a well-established proton-pump inhi-
bitor (PPI) that has been recently approved in the USA and
EU as an over-the-counter (OTC) medication for short-
term treatment (up to 14 days) of reflux symptoms such as
heartburn and acid regurgitation [12, 13]. Results from two
similarly designed, randomized, double-blind, placebo-
controlled trials have previously shown that 4 weeks of
esomeprazole treatment was significantly effective in
relieving nighttime heartburn and improving sleep quality
and work productivity [14, 15]. The population enrolled in
these trials was selected based on the occurrence of fre-
quent nighttime heartburn or acid regurgitation and sleep
disturbance caused by these symptoms. These trials,
therefore, are important to our understanding of the role of
PPI treatment in the management of nighttime heartburn
and its consequences, in particular, the significant negative
impact of sleep disruptions in those experiencing reflux
symptoms. Since information in the literature is lacking in
this area, particularly in the OTC PPI arena, exploring
these issues may help guide healthcare professionals in
their counseling of patients who suffer from heartburn-re-
lated sleep disturbances in order to establish appropriate
expectations for response to treatment. Accordingly, the
current analysis sought to identify predictive factors from
these two trials that are associated with the complete res-
olution of sleep disturbance due to heartburn or other reflux
symptoms in subjects with frequent nighttime heartburn or
acid regurgitation and sleep disturbance related to these
symptoms [14, 15]. These analyses focus on outcomes with
esomeprazole 20 mg from the first 14 days to align with
the dose and duration approved for OTC use.
2 Patients and Methods
Data were derived from two identical, multicenter, double-
blind, placebo-controlled studies conducted in the USA
(ClinicalTrials.gov, numbers NCT00628342 and
NCT00660660). The conduct of and the primary results
from these studies at 4 weeks have been described previ-
ously [14, 15]. Written informed consent was obtained
from all subjects, the studies were conducted in accordance
with the Declaration of Helsinki, and each study was
approved by local Institutional Review Boards.
2.1 Subjects
The populations for both studies were male and female
subjects aged 18–85 years with histories of frequent
nighttime heartburn (defined as an average of C2 times per
week), histories of heartburn or acid regurgitation for
C3 months or any history of erosive esophagitis, and his-
tories of sleep disturbance associated with heartburn or
other symptoms of gastroesophageal reflux for C1 month.
At the screening assessment, eligible subjects were enrol-
led in a 7- to 15-day run-in period, during which they
recorded the severity of episodes of daytime or nighttime
heartburn or other gastroesophageal reflux disease (GERD)
symptoms (none, mild, moderate, severe), as well as the
occurrence of sleep disturbance related to GERD symp-
toms (‘‘Yes’’ or ‘‘No’’) on a daily diary card. Subjects were
required to have sleep disturbance associated with GERD
and documented moderate-to-severe nighttime heartburn
during C3 of the last 7 days of the run-in period. Sleep
disturbance included, but was not limited to, trouble falling
asleep, unwanted awakenings, or overall poor sleep quality.
Exclusion criteria included presence of, or treatment for,
conditions other than reflux that may contribute to sleep
disturbance or compromise study procedures, including
shift work between 12 am (midnight) and 6 am and plans to
travel beyond three time zones during the course of the
study; use of PPIs; and drug or alcohol abuse within the
past 12 months.
2.2 Treatment
Subjects in the original studies were treated with
esomeprazole 20 mg (both trials), esomeprazole 40 mg
(study 1 only), or placebo, all administered once daily in
the morning before breakfast for 4 weeks. Esomeprazole
20 mg was taken orally and administered as 22.3 mg
esomeprazole magnesium trihydrate (Nexium; AstraZe-
neca LP, Wilmington, DE, USA). For the purposes of this
analysis only, esomeprazole 20 mg data from the first
14 days were utilized, which is consistent with the
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approved OTC dosage and duration for PPIs. The only
medication allowed for treatment of heartburn during the
run-in period was the assigned rescue medication: Gelusil
(alumina, magnesia, and simethicone; WellSpring Phar-
maceutical Corp, Sarasota, FL, USA). Gelusil tablets were
also permitted as rescue medication for heartburn during
the treatment phase (up to 6 per 24-h period).
2.3 Outcome Measures
The focus of the analysis presented here was on data col-
lected during the first 14 days on study treatment. The a
priori-defined primary endpoint of the 2 studies was relief
of nighttime heartburn during the last 7 days of the 28-day
treatment period. Although analyses at the 14-day time
point were predefined in the studies’ statistical plans for
most outcomes, post hoc analyses were required for the
data reported here.
All subjects attended follow-up visits 2 and 4 weeks
after the start of randomized treatment. The occurrence of
reflux-related sleep disturbance and severity of heartburn
episodes were recorded by subjects in a daily self-assess-
ment diary.
Key endpoints of interest for the analysis presented here
were complete resolution (yes or no) of sleep disturbance
due to heartburn or other symptoms of gastroesophageal
reflux (defined as no reflux-related sleep disturbance on 7
consecutive days), complete relief (yes or no) of sleep
disturbance due to heartburn or other symptoms of gas-
troesophageal reflux (defined as reflux-related sleep dis-
turbance on B1 of 7 consecutive days), and relief (yes or
no) of sleep disturbance due to heartburn or other symp-
toms of gastroesophageal reflux (defined as reflux-related
sleep disturbance on B2 of 7 days).
2.4 Statistical Analysis
Efficacy analyses were performed on a modified intention-
to-treat population, which included all randomized subjects
who took at least one dose of study medication and had
post-treatment data. Logistic regression analyses were
performed to identify predictors of the various sleep dis-
turbance outcomes of interest following treatment with
esomeprazole 20 mg or placebo through day 14. The three
endpoints were analyzed separately using a stepwise
logistic regression model incorporating different variables,
including treatment group assignment (esomeprazole vs.
placebo), study, site, age, gender, frequency of sleep dis-
turbance reported during the run-in period, and the occur-
rence (yes/no) of 24-h, daytime, and nighttime heartburn,
defined as C1 episode during the 14-day treatment period.
A number of models were developed for each endpoint,
and results of the models with the best fit according to
deviance and Akaike information criteria are reported. The
level of significance for variables to remain in the final
model was set at 0.2. However, variables were only con-
sidered important predictors if they were significant at the
0.05 level. Some models were generated by including and
excluding the occurrence of heartburn during treatment to
ensure that this factor would not impact the identification
of major risk factors.
Sleep disturbance frequency during the run-in period
was evaluated as both a continuous and categorical variable
in the different models. Body mass index (BMI) data were
available for only study 2; therefore, a separate analysis
was conducted of study 2 alone that took BMI into account,
both as a continuous and categorical variable. Analyses
were conducted using SAS v. 9.2 (Cary, NC, USA).
3 Results
3.1 Subject Characteristics
Table 1 shows baseline characteristics of subjects enrolled
in the two studies [14, 15], as well as the pooled dataset,
which included 703 subjects from the two studies
(esomeprazole 20 mg: n = 357; placebo: n = 346). Sub-
jects were predominately white females with a mean age of
approximately 47 years.
3.2 Predictors of Complete Resolution
In the best-fit logistic regression model of complete reso-
lution of sleep disturbance due to heartburn or other reflux
symptoms, treatment with esomeprazole 20 mg [adjusted
odds ratio (OR) 2.39; 95 % confidence interval (CI)
1.70–3.36; p\ 0.0001], absence of daytime heartburn
during treatment (adjusted OR 3.50; 95 % CI 1.59–7.69;
p = 0.0018), and absence of nighttime heartburn during
treatment (adjusted OR 12.07; 95 % CI 3.53–41.22;
p\ 0.0001) were found to be significant positive predic-
tors of complete resolution in the overall population (i.e.
those receiving esomeprazole 20 mg or placebo) at 14 days
(Table 2), while subjects with higher frequency of sleep
disturbance during the run-in period were less likely to
have complete resolution of symptoms in the total popu-
lation (adjusted OR 0.80; 95 % CI 0.72–0.89; p\ 0.0001).
The frequency of sleep disturbance during the run-in period
was a statistically significant predictor when analyzed as
both a continuous (p\ 0.0001) and a categorical
(p = 0.0001) variable.
A greater proportion of subjects treated with
esomeprazole 20 mg experienced complete resolution of
sleep disturbance due to heartburn or other reflux symp-
toms over 14 days of treatment compared with placebo,
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regardless of the frequency of sleep disturbance during the
run-in period (Fig. 1). As the frequency of run-in sleep
disturbance increased, the rates of complete resolution of
sleep disturbance progressively decreased in all subjects
(as would be expected), while the relative difference
between esomeprazole and placebo increased in favor of
esomeprazole in a stepwise manner. A separate analysis
was conducted for complete resolution where the interac-
tion between run-in sleep disturbance frequency and
treatment effect was added to the model, and a significant
effect was observed for the interaction (p = 0.0231),
confirming a greater therapeutic benefit with esomeprazole
in the subgroups with higher levels of run-in symptom
frequency.
Table 1 Baseline characteristics of study population















46.8 (14.0) 46.5 (13.6) 47.0 (11.7) 46.8 (12.9) 46.9 (13.1) 46.6 (13.3)
Female, n (%) 132 (60.0) 131 (59.3) 89 (65.0) 85 (68.0) 221 (61.9) 216 (62.4)
Male, n (%) 88 (40.0) 90 (40.7) 48 (35.0) 40 (32.0) 136 (38.1) 130 (37.6)
Race, n (%)
White/Caucasian 190 (86.4) 186 (84.2) 105 (76.6) 104 (83.2) 295 (82.6) 290 (83.8)
Black/African
American
16 (7.3) 17 (7.7) 25 (18.2) 13 (10.4) 41 (11.5) 30 (8.7)
Other 14 (6.4) 18 (8.1) 7 (5.1) 8 (6.4) 21 (5.9) 26 (7.5)
BMI (kg/m2), mean
(SD)
– – 30.3 (6.9) 30.9 (7.4) – –
Run-in sleep disturbance, n (%)
B3 days 74 (33.6) 63 (28.5) 48 (35.0) 35 (28.0) 122 (34.2) 98 (28.3)
4–5 days 89 (40.5) 84 (38.0) 48 (35.0) 48 (38.4) 137 (38.4) 132 (38.2)
6–7 days 57 (25.9) 74 (33.5) 41 (29.9) 42 (33.6) 98 (27.5) 116 (33.5)
BMI body mass index, ESO esomeprazole, SD standard deviation
Table 2 Predictors of sleep disturbance endpoints due to heartburn or other reflux symptoms at 14 days: final model
Logistic regression analysis factor Complete resolutiona odds ratio
(95 % CI); p value
Complete reliefb odds ratio
(95 % CI); p value
Reliefc odds ratio (95 %
CI); p value












Not kept in the model Not kept in the model






















No vs. yes 12.07 (3.53–41.22)
\0.0001
4.96 (1.08–22.84) 0.0400 4.40 (0.94–20.54)
0.0595
CI confidence interval
a Defined as no sleep disturbance due to heartburn or other reflux symptoms on 7 consecutive days
b Defined as sleep disturbance due to heartburn or other reflux symptoms on B1 of 7 consecutive days
c Defined as sleep disturbance due to heartburn or other reflux symptoms on B2 of 7 consecutive days
d Continuous variable
e Presence of daytime and nighttime heartburn defined as C1 episode during 14-day treatment period
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Subjects in both treatment groups without any episodes
of daytime or nighttime heartburn during the 14-day
treatment period had higher rates of complete resolution of
sleep disturbance due to heartburn or other reflux symp-
toms compared with those who continued to have one or
more episodes of heartburn during the treatment period
(Fig. 2).
3.3 Predictors of Complete Relief and Relief
of Sleep Disturbance
Consistent with the analyses of complete resolution, in the
best-fit logistic regression model, treatment with
esomeprazole 20 mg compared with placebo and run-in
sleep disturbance frequency were found to be significantly
important predictors of complete relief (treatment group
assignment: adjusted OR 2.28; 95 % CI 1.56–3.32;
p\ 0.0001; run-in sleep disturbance frequency: adjusted
OR 0.58; 95 % CI 0.52–0.66; p\ 0.0001) and relief
(treatment group assignment: adjusted OR 2.19; 95 % CI
1.48–3.24; p\ 0.0001; run-in sleep disturbance frequency:
adjusted OR 0.56; 95 % CI 0.49–0.64; p\ 0.0001) of
reflux-associated sleep disturbance. In separate analyses
conducted for complete relief and relief where an interac-
tion term was added to the model, significant treatment by
run-in sleep disturbance frequency interaction was
observed for complete relief (p = 0.0286) and relief
(p = 0.0425), suggesting that the therapeutic effect of
esomeprazole over placebo on these outcomes was greater
in those with higher frequency of run-in symptoms. Also
consistent with complete resolution, absence of nighttime
heartburn during treatment was significantly predictive of
complete relief (adjusted OR 4.96; 95 % CI 1.08–22.84;
p = 0.0400) and was borderline significantly predictive for
relief (adjusted OR 4.40; 95 % CI 0.94–20.54;
p = 0.0595). Daytime heartburn during treatment was a
borderline significant predictor (adjusted OR 2.66; 95 % CI
0.93–7.63; p = 0.0678), and gender was found not to be
significantly predictive (adjusted OR 0.77; 95 % CI
0.52–1.12; p = 0.1752) of complete relief; gender was not
analyzed for relief of sleep disturbances.
Separate logistic regression analyses of study 2 were
conducted to examine the impact of baseline BMI. BMI as
either a continuous or categorical variable was not an
important predictor of outcome in any of the models.
4 Discussion
Treatment with esomeprazole 20 mg was an important
positive predictor of complete resolution of heartburn/reflux-
related sleep disturbance in this analysis, while higher fre-
quency of sleep disturbances during the run-in period was an
important negative predictor of sleep disturbance resolution.
Other factors that were significant predictors for some but
not all endpoints of interest were the occurrence of nighttime
and daytime heartburn after the start of treatment and study
enrollment. BMI, gender, age, and 24-h heartburn were not
significant predictors of complete resolution, complete
relief, or relief of sleep disturbance. These results are in
agreement with those of a previous study by Jansson et al.,
who found a significant relationship between GERD and
sleep problems, but found that age, gender, tobacco use,
BMI, or socioeconomic status had no impact [16].
In subjects who are likely to self-treat their reflux
symptoms without consulting a healthcare provider,
14 days of treatment with esomeprazole 20 mg for frequent
heartburn has been shown to be effective at improving both
Fig. 1 Effect of run-in frequency of sleep disturbance on complete
resolution of sleep disturbance due to heartburn or other reflux
symptoms by 14 days. *p\ 0.0001
Fig. 2 Effect of the presence/absence of daytime and nighttime
heartburn on complete resolution of sleep disturbance due to
heartburn or other reflux symptoms by 14 days (Presence of daytime
and nighttime heartburn defined as C1 episode during 14-day
treatment period)
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daytime and nighttime symptoms [17]. Other studies have
also demonstrated improvements in sleep quality following
effective treatment for reflux symptoms [18, 19]. Previous
analysis of the current dataset has demonstrated that
esomeprazole was associated with rapid resolution and
relief of sleep disturbance and improvement in sleep
quality that was significantly superior to that seen with
placebo; improvements were seen as early as the first night
of treatment [20]. The predictive nature of esomeprazole
treatment with regard to resolution and relief of sleep
disturbance after 14 days was, therefore, to be expected.
However, the noticeable reduction in the likelihood of
sleep disturbance resolution in those with persistent day-
time and nighttime symptoms during treatment may reflect
the more severe nature of these symptoms when they are
experienced nocturnally [21, 22]. Importantly, guidelines
for self-treating frequent heartburn with an OTC PPI rec-
ommend that those with symptoms that persist following a
2-week treatment course with an OTC PPI should be
referred to a physician for further evaluation [23]. It is
likely that certain individuals who are experiencing per-
sistent symptoms during PPI treatment may require a more
aggressive treatment strategy that is provided under the
direction of a physician to effectively manage these
symptoms.
The importance of understanding sleep disturbances in
those experiencing reflux symptoms has been demonstrated
in a number of trials. Although nocturnal acid reflux
symptoms tend to occur less frequently than daytime
symptoms, they are associated with longer acid-esophageal
contact time, resulting in an increased risk of mucosal
damage [21, 22]. Nocturnal acid reflux-related symptoms
that are associated with sleep disturbances have also been
linked to impaired health-related quality of life and
decreased functioning and productivity the following day
[1, 2, 5, 6]. In one study, the negative effect of sleep
dysfunction on quality of life was surpassed only by the
dimensions of ‘‘eating and drinking problems’’ and ‘‘vi-
tality’’ [24]. Improvement in sleep quality following PPI
therapy has been demonstrated in a number of trials to date
[14, 15, 18, 19]. These improvements have also been
shown to correlate with improved work productivity and
daily activities [14, 15]. A systematic review by Tack et al.
of 19 studies suggested that decreased sleep quality due to
nocturnal reflux symptoms impairs work productivity by
causing daytime sleepiness, a phenomenon compounded by
successive nights of poor sleep quality [25]. Although the
adverse socioeconomic impact of heartburn-related sleep
disturbance has been well reported in the medical litera-
ture, these effects are likely not well recognized by the
individuals or pharmacists who frequently counsel on the
use of OTC treatments. The adverse impact of heartburn-
related sleep disturbance may be further compounded if the
patient fails to recognize these events or report them
when questioned about sleep efficiency by a clinician.
Sleep has an amnestic effect, so patients who awaken
from these acid reflux-related events may fail to recall
them in the morning.
In a 2000 mail survey, 130,000 individuals reported that
they had signs of reflux disease and heartburn. Of these,
95 % reported symptoms occurring for more than 1 year
and half reported symptoms that had occurred for more
than 5 years. Seventy-five percent reported that the
symptoms occurred at least twice a week [9]. Results of a
US general population survey of 11,685 participants
showed that GERD-related sleep disturbance was associ-
ated with a 5.5 % increase in overall work impairment and
a 10.9 % increase in activity impairment [7]. In their sys-
tematic review, Tack et al. compared the burden of dis-
ruptive GERD, defined as GERD with frequent and/or
severe symptoms, with non-disruptive GERD and found
that disruptive GERD was associated with sleep quality
scores 1.5 times lower than those for non-disruptive GERD
[25]. Impaired sleep quality was found to be significantly
associated with nocturnal and daytime reflux symptoms
(p\ 0.05), as well as greater overall severity of symptoms
(p\ 0.05). Additionally, nocturnal symptoms have been
shown to be associated with a greater degree of impairment
in health-related quality of life when compared with those
with daytime symptoms only [26]. Tack et al. also
reviewed the impact of GERD on work productivity among
studies that utilized the Work Productivity and Activity
Impairment questionnaire and found that the mean number
of hours absent from work was 2.4 times higher in the
disruptive GERD group compared with the non-disruptive
GERD group [25]. Similar to the impact of disruptive
GERD on sleep, more-frequent and severe symptoms were
associated with decreased work productivity. Interestingly,
the mean number of hours absent from work due specifi-
cally to reflux symptoms was similar between those with
frequent nocturnal symptoms and those with occasional to
no nocturnal symptoms, suggesting that the sleep disrup-
tions, not reflux symptoms, had the greatest impact on
work productivity. These data emphasize the importance of
effectively managing reflux-related sleep disturbances to
alleviate the substantial burden that is observed among
those experiencing these symptoms.
The current analyses have important strengths that are
worth noting, including the use of prospective data from
randomized, placebo-controlled trials that performed
comprehensive assessments of reflux symptoms and sleep-
related endpoints beginning on the first day of treatment.
Data from randomized, controlled trials evaluating the
efficacy of OTC PPIs for these outcomes are limited in the
literature, so these analyses provide important information
about clinical factors that are related to resolution of reflux-
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related sleep disturbances. However, these analyses also
have a number of limitations. First, this was a retrospective
analysis of two previously published trials [14, 15]. The
primary endpoint for these trials was complete relief of
nighttime heartburn during the last 7 days of the 4-week
treatment period, whereas the current analysis evaluated
outcomes during the first 2 weeks. Furthermore, the other
endpoints included in the current analysis—complete res-
olution and relief of sleep disturbance—were not primary
endpoints but rather secondary endpoints in these trials.
Because outcomes related to sleep quality and work pro-
ductivity were only collected at baseline and week 4, we
were unable to include these measures in the current
analysis. Additionally, the populations that were studied
may have included some subjects with more serious con-
ditions who would not be ideal candidates for self-man-
agement in the OTC setting without any physician
oversight. Specifically, the studies enrolled subjects with a
history of heartburn for C3 months and/or a history of
erosive esophagitis—patients in whom consultation with a
physician is recommended prior to initiating OTC PPIs.
Despite this limitation, the frequent occurrence of noctur-
nal symptoms and sleep disturbances in this population,
coupled with the fact that many individuals with GERD
avoid or delay consulting a healthcare provider (with cost
of prescription treatment being a potential barrier) [27],
underscore the importance of exploring this issue and
understanding the response to treatment with an OTC PPI.
The current analysis was focused on treatment that was
consistent in dose and duration with OTC management of
symptoms and thus did not include patients treated with
esomeprazole 40 mg in study 1 of the original studies [14].
However, given the lack of differences in the primary
efficacy results between the two dosing groups in study 1,
we did not anticipate that the results with the 40 mg dose
would have differed in a meaningful way from those
observed with the 20 mg dose. Finally, our analysis was
not able to assess the likelihood of a recurrence following
cessation of treatment. Future studies with similar end-
points in individuals with histories of chronic heartburn
would benefit from inclusion of a post-treatment follow-up
period to evaluate the risk for recurrence once the active
treatment is withdrawn.
5 Conclusions
In the overall population (esomeprazole- and placebo-treated
subjects), increasing frequency of sleep disturbance during
the run-in period and the persistence of nighttime heartburn
during the 14-day treatment period were associated with a
reduced likelihood of experiencing both complete resolution
and complete relief of sleep disturbance due to heartburn or
other reflux symptoms. However, analyses of treatment
effects found that treatment with esomeprazole 20 mg was
an independent and statistically significant predictor of
successful outcome in all models; the odds of complete
resolution, complete relief, and relief of sleep disturbance
associated with reflux symptoms in subjects who received
esomeprazole 20 mg were more than twice the odds of those
treated with placebo. These therapeutic effects were con-
sistent in those with or without continued daytime or
nighttime heartburn during treatment. Treatment with
esomeprazole was associated with greater improvement
versus placebo across all categories of run-in sleep distur-
bance frequency. The magnitude of therapeutic benefit for
esomeprazole 20 mg relative to placebo, however, was
significantly greater in those with more-frequent run-in sleep
disturbances. These findings suggest that individuals with a
lower incidence of run-in sleep disturbance will be more
likely to experience improvements in sleep disturbance
whether they are treated with an active or inactive treatment.
Those with a higher incidence of run-in sleep disturbance,
however, may be more likely to benefit specifically from
treatment with esomeprazole. For individuals experiencing
nighttime heartburn and related sleep disturbance,
esomeprazole is likely to have a significant clinical impact
on their well-being, even among those with high levels of
baseline sleep disturbance.
Acknowledgments The studies were funded by AstraZeneca, which
entered into an agreement with Pfizer for the over-the-counter (OTC)
rights for NEXIUM (esomeprazole magnesium). Medical writing
support was provided by Dennis Stancavish, MA, of Peloton
Advantage, LLC, and was funded by Pfizer. This manuscript includes
data owned by AstraZeneca.
Compliance with Ethical Standards
Conflict of interest disclosures David A. Johnson, MD, is a con-
sultant to Pfizer, Medscape/WebMD, and Covidien (Medtronic) and
was a paid consultant to Pfizer in connection with the development of
this manuscript. Anne Le Moigne, Jing Li, PhD, and Charles Pollack,
MD, are employees of Pfizer Consumer Healthcare. Peter Nagy, MD,
is an employee of AstraZeneca AB.
Ethical approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
Informed consent Informed consent was obtained from all indi-
vidual participants included in the studies.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
Predictors of Heartburn/Reflux-Related Sleep Disturbance Resolution 537
References
1. Gerson LB, Fass R. A systematic review of the definitions,
prevalence, and response to treatment of nocturnal gastroe-
sophageal reflux disease. Clin Gastroenterol Hepatol.
2009;7:372–8.
2. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn
is an under-appreciated clinical problem that impacts sleep and
daytime function: the results of a Gallup survey conducted on
behalf of the American Gastroenterological Association. Am J
Gastroenterol. 2003;98:1487–93.
3. Ryden A, Martin M, Halling K, et al. Night-time symptoms and
their impact on sleep in patients with gastroesophageal reflux
disease who have a partial response to proton pump inhibitors: a
qualitative patient interview study. Patient. 2013;6:307–14.
4. Dent J, Holloway RH, Eastwood PR. Systematic review: rela-
tionships between sleep and gastro-oesophageal reflux. Aliment
Pharmacol Ther. 2013;38:657–73.
5. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal
symptoms associated with gastroesophageal reflux disease on
health-related quality of life. Arch Intern Med. 2001;161:45–52.
6. Dean BB, Aguilar D, Johnson LF, et al. Night-time and daytime
atypical manifestations of gastro-oesophageal reflux disease:
frequency, severity and impact on health-related quality of life.
Aliment Pharmacol Ther. 2008;27:327–37.
7. Mody R, Bolge SC, Kannan H, et al. Effects of gastroesophageal
reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol.
2009;7:953–9.
8. Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent
nocturnal gastro-oesophageal reflux disease among employed
adults: symptom severity, quality of life and work productivity.
Aliment Pharmacol Ther. 2007;25:487–500.
9. Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux
disease in primary care: the patient perspective. J Am Board Fam
Pract. 2005;18:393–400.
10. Besedovsky L, Lange T, Born J. Sleep and immune function.
Pflugers Arch. 2012;463:121–37.
11. Ali T, Choe J, Awab A, et al. Sleep, immunity and inflammation
in gastrointestinal disorders. World J Gastroenterol.
2013;19:9231–9.
12. Nexium 24HR [product labeling]. Madison: Pfizer Consumer
Healthcare; 2014.
13. Nexium Control (esomeprazole) [summary of product charac-
teristics]. Kent: Pfizer Consumer Healthcare Ltd.; 2014.
14. Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole
on nighttime heartburn and sleep quality in patients with GERD:
a randomized, placebo-controlled trial. Am J Gastroenterol.
2005;100:1914–22.
15. Johnson DA, Crawley JA, Hwang C, et al. Clinical trial:
esomeprazole for moderate-to-severe nighttime heartburn and
gastro-oesophageal reflux disease-related sleep disturbances.
Aliment Pharmacol Ther. 2010;32:182–90.
16. Jansson C, Nordenstedt H, Wallander MA, et al. A population-
based study showing an association between gastroesophageal
reflux disease and sleep problems. Clin Gastroenterol Hepatol.
2009;7:960–5.
17. Peura DA, Traxler B, Kocun C, et al. Esomeprazole treatment of
frequent heartburn: two randomized, double-blind, placebo-con-
trolled trials. Postgrad Med. 2014;126:33–41.
18. Shaheen NJ, Madanick RD, Alattar M, et al. Gastroesophageal
reflux disease as an etiology of sleep disturbance in subjects with
insomnia and minimal reflux symptoms: a pilot study of preva-
lence and response to therapy. Dig Dis Sci. 2008;53:1493–9.
19. Yi CH, Chen CL, Kuo TB, et al. The effect of acid suppression on
sleep and cardiac autonomic regulation in GERD. Hepatogas-
troenterology. 2008;55:1649–52.
20. Johnson DA, Le Moigne A, Hugo V, et al. Rapid resolution of
sleep disturbances related to frequent reflux: effect of
esomeprazole 20 mg in 2 randomized, double-blind, controlled
trials. Curr Med Res Opin. 2015;31:243–50.
21. Kanaly T, Shaheen NJ, Vaughn BV. Gastrointestinal physiology
and digestive disorders in sleep. Curr Opin Pulm Med.
2009;15:571–7.
22. Orr WC, Johnson LF, Robinson MG. Effect of sleep on swal-
lowing, esophageal peristalsis, and acid clearance. Gastroen-
terology. 1984;86:814–9.
23. Hunt R, Quigley E, Abbas Z, et al. Coping with common gas-
trointestinal symptoms in the community: a global perspective on
heartburn, constipation, bloating, and abdominal pain/discomfort
May 2013. J Clin Gastroenterol. 2014;48:567–78.
24. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to
symptoms in patients with gastro-oesophageal reflux disease—an
analysis based on the ProGERD initiative. Aliment Pharmacol
Ther. 2003;18:767–76.
25. Tack J, Becher A, Mulligan C, et al. Systematic review: the burden
of disruptive gastro-oesophageal reflux disease on health-related
quality of life. Aliment Pharmacol Ther. 2012;35:1257–66.
26. Ponce J, Beltran B, Ponce M, et al. Impact of gastroesophageal
reflux disease on the quality of life of Spanish patients: the rel-
evance of the biometric factors and the severity of symptoms. Eur
J Gastroenterol Hepatol. 2009;21:620–9.
27. Hungin AP, Hill C, Raghunath A. Systematic review: frequency
and reasons for consultation for gastro-oesophageal reflux disease
and dyspepsia. Aliment Pharmacol Ther. 2009;30:331–42.
538 D. A. Johnson et al.
